
ADVANCE-ID celebrates the publication of its first study, the ACORN-HAI (A Clinically-Oriented Antimicrobial Resistance Surveillance Network – Healthcare-Associated Infections) study, in The Lancet Infectious Diseases on 21 August 2026.
This multicentre prospective cohort study enrolled more than 10,000 patients across 19 countries and regions in Asia, reflecting an extensive collaborative effort by investigators, clinical teams and participating patients.
The study’s analytics highlighted alarmingly high crude and attributable mortality associated with antimicrobial resistance (AMR) among patients with severe healthcare-associated infections.
The findings underscore the urgent challenge of access to effective antimicrobial treatment in Asia. Patients included in the study did not have access to newer antibiotics such as sulbactam-durlobactam and cefiderocol, while treatment options often remained limited to older agents including polymyxins and, in some settings, ceftazidime-avibactam.
The study raises an important question for healthcare systems and research communities: how can patients across Asia gain timely access to more effective antibiotic therapies?
ADVANCE-ID extends its sincere thanks to Wellcome for funding the study, to the investigator teams across the network, and especially to the patients and families whose participation made this research possible.
Read the full study:
The findings from the ACORN-HAI study have been published in The Lancet Infectious Diseases. We invite you to explore the full research article to learn more about the burden of antimicrobial resistance and its impact on patient outcomes across Asia.
